RE:RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway Perspectives:
Although 5 decades of research have yielded many failures, "vaccines"; such as ONCY's platfrom drug pelareorep, are now positioned for success for several reasons.
Compared to prior decades, it is now clear that (1) T cells can treat (and, in some instances, cure) patients with cancer, as seen with CAR T cells and bispecific T cell engagers; 2) patients' endogenous T cells can be primed against their own TAAs, correlating with tumor regression, as seen with checkpoint blockade; and 3) priming of endogenous T cells requires optimal antigen presentation (for example, cDC1 cells). which pelareorep is able to accomplish.